Vext Science 過去の業績
過去 基準チェック /06
Vext Science has been growing earnings at an average annual rate of 1.2%, while the Pharmaceuticals industry saw earnings growing at 13.1% annually. Revenues have been growing at an average rate of 10.5% per year.
主要情報
1.2%
収益成長率
-2.7%
EPS成長率
| Pharmaceuticals 業界の成長 | 7.3% |
| 収益成長率 | 10.5% |
| 株主資本利益率 | -8.0% |
| ネット・マージン | -20.8% |
| 前回の決算情報 | 30 Jun 2024 |
最近の業績更新
Recent updates
収支内訳
Vext Science の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。
収益と収入の歴史
| 日付 | 収益 | 収益 | G+A経費 | 研究開発費 |
|---|---|---|---|---|
| 30 Jun 24 | 33 | -7 | 16 | 0 |
| 31 Mar 24 | 34 | -2 | 14 | 0 |
| 31 Dec 23 | 35 | 4 | 14 | 0 |
| 30 Sep 23 | 35 | 5 | 8 | 0 |
| 30 Jun 23 | 34 | 7 | 8 | 0 |
| 31 Mar 23 | 34 | 9 | 10 | 0 |
| 31 Dec 22 | 35 | 11 | 10 | 0 |
| 30 Sep 22 | 37 | 6 | 9 | 0 |
| 30 Jun 22 | 38 | 6 | 7 | 0 |
| 31 Mar 22 | 39 | 6 | 7 | 0 |
| 31 Dec 21 | 37 | 5 | 6 | 0 |
| 30 Sep 21 | 34 | 5 | 6 | 0 |
| 30 Jun 21 | 33 | 5 | 6 | 0 |
| 31 Mar 21 | 30 | 4 | 5 | 0 |
| 31 Dec 20 | 25 | 2 | 5 | 0 |
| 30 Sep 20 | 22 | 0 | 6 | 0 |
| 30 Jun 20 | 20 | 0 | 6 | 0 |
| 31 Mar 20 | 20 | 0 | 6 | 0 |
| 31 Dec 19 | 22 | 3 | 5 | 0 |
| 30 Sep 19 | 23 | 4 | 4 | 0 |
| 30 Jun 19 | 23 | 5 | 4 | 0 |
| 31 Mar 19 | 21 | 4 | 3 | 0 |
| 31 Dec 18 | 18 | 4 | 3 | 0 |
| 31 Dec 17 | 15 | 4 | 2 | 0 |
質の高い収益: VV5 is currently unprofitable.
利益率の向上: VV5 is currently unprofitable.
フリー・キャッシュフローと収益の比較
過去の収益成長分析
収益動向: VV5 is unprofitable, but has reduced losses over the past 5 years at a rate of 1.2% per year.
成長の加速: Unable to compare VV5's earnings growth over the past year to its 5-year average as it is currently unprofitable
収益対業界: VV5 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (28.7%).
株主資本利益率
高いROE: VV5 has a negative Return on Equity (-7.97%), as it is currently unprofitable.